Compare AUROW & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUROW | INM |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 7.1M |
| IPO Year | 2021 | 2020 |
| Metric | AUROW | INM |
|---|---|---|
| Price | $0.07 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.6K | ★ 66.9K |
| Earning Date | 04-30-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.35 | ★ 62.68 |
| EPS | ★ N/A | N/A |
| Revenue | $3,000,000.00 | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.04 | $0.58 |
| 52 Week High | $0.87 | $2.50 |
| Indicator | AUROW | INM |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 35.71 |
| Support Level | N/A | $1.03 |
| Resistance Level | $0.25 | $1.40 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 7.87 | 13.04 |
Aurora Innovation is a US autonomous driving provider for heavy trucks. The company produces and sells its Aurora Driver system, which includes hardware installed in a vehicle, software to autonomously drive it, and data management to maintain and improve the software. Aurora targets long-haul routes. The company currently offers its trucking-as-a-service model, where it owns and operates the trucks and makes deliveries for customers. The company plans to start selling its driver-as-a-service model next year, where fleet owners will own the trucks and Aurora's software will operate them.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.